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Abstract
Background: Inflammation or nerve injury-induced upregulation and release of chemokine CC chemokine ligand 2
(CCL2) within the dorsal root ganglion (DRG) is believed to enhance the activity of DRG nociceptive neurons and
cause hyperalgesia. Transient receptor potential vanilloid receptor 1 (TRPV1) and tetrodotoxin (TTX)-resistant Nav1.8
sodium channels play an essential role in regulating the excitability and pain transmission of DRG nociceptive
neurons. We therefore tested the hypothesis that CCL2 causes peripheral sensitization of nociceptive DRG neurons
by upregulating the function and expression of TRPV1 and Nav1.8 channels.
Methods: DRG neuronal culture was prepared from 3-week-old Sprague–Dawley rats and incubated with various
concentrations of CCL2 for 24 to 36 hours. Whole-cell voltage-clamp recordings were performed to record TRPV1
agonist capsaicin-evoked inward currents or TTX-insensitive Na+ currents from control or CCL2-treated small DRG
sensory neurons. The CCL2 effect on the mRNA expression of TRPV1 or Nav1.8 was measured by real-time
quantitative RT-PCR assay.
Results: Pretreatment of CCL2 for 24 to 36 hours dose-dependently (EC50 value = 0.6 ± 0.05 nM) increased the
density of capsaicin-induced currents in small putative DRG nociceptive neurons. TRPV1 mRNA expression was
greatly upregulated in DRG neurons preincubated with 5 nM CCL2. Pretreating small DRG sensory neurons with
CCL2 also increased the density of TTX-resistant Na+ currents with a concentration-dependent manner (EC50
value = 0.7 ± 0.06 nM). The Nav1.8 mRNA level was significantly increased in DRG neurons pretreated with CCL2. In
contrast, CCL2 preincubation failed to affect the mRNA level of TTX-resistant Nav1.9. In the presence of the specific
phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 or Akt inhibitor IV, CCL2 pretreatment failed to increase the
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Conclusions: Our results showed that CCL2 increased the function and mRNA level of TRPV1 channels and Nav1.8
sodium channels in small DRG sensory neurons via activating the PI3K/Akt signaling pathway. These findings
suggest that following tissue inflammation or peripheral nerve injury, upregulation and release of CCL2 within the
DRG could facilitate pain transmission mediated by nociceptive DRG neurons and could induce hyperalgesia by
upregulating the expression and function of TRPV1 and Nav1.8 channels in DRG nociceptive neurons.
Keywords: CC chemokine ligand 2, Dorsal root ganglion neurons, Transient receptor potential vanilloid receptor 1,
Tetrodotoxin-resistant Nav1.8 sodium channel
Background
Following tissue inflammation or peripheral nerve injury,
several chemokines are released by invading immune
cells or resident cells and believed to enhance the activ-
ity of nociceptive dorsal root ganglion (DRG) neurons,
leading to hyperalgesia, allodynia and spontaneous pain
[1-4]. Multiple lines of evidence suggest that chemokine
CC chemokine ligand 2 (CCL2)/monocyte chemoattract-
ant protein-1 plays an important role in mediating the
peripheral sensitization of nociceptive DRG neurons and
pain hypersensitivity of inflammatory or neuropathic
pain [1,3,5]. Chemokine (C-C motif ) receptor 2 (CCR2),
the preferred receptor for CCL2, is expressed in DRG
neurons, and CCL2 directly excites nociceptive DRG
neurons [6,7]. Expression of CCL2 or CCR2 in neuronal
and glial cells of the DRG has been shown to be upregu-
lated in several animal models of inflammatory or
neuropathic pain [8-14]. CCL2 expressed by DRG neu-
rons is packaged into large dense core vesicles and
released from activated DRG neurons [15]. Transgenic
mice overexpressing CCL2 exhibited greater edema and
augmented thermal hyperalgesia following tissue inflam-
mation [16]. Tissue inflammation-induced or nerve
injury-induced upregulation and release of CCL2 within
the DRG could therefore enhance pain transmission
mediated by nociceptive DRG neurons and induce
hyperalgesia. The exact molecular mechanism by which
CCL2 facilitates the nociceptive transmission of DRG
nociceptive neurons is not completely understood.
Transient receptor potential vanilloid receptor 1
(TRPV1) is a nonselective cation channel mainly
expressed in small-diameter and medium-diameter DRG
sensory neurons and activated by capsaicin, noxious heat
and low pH [17]. Activation of TRPV1 by noxious stim-
uli, which induces inward cationic currents and resulting
action potentials in nociceptive DRG neurons, is respon-
sible for conveying nociceptive information to spinal
dorsal horn [18-20]. Under pathological conditions,
TRPV1 expression in nociceptive DRG neurons is upre-
gulated in the animal model of complete Freund’s
adjuvant-induced inflammation or peripheral neuropathy
[21-24]. Furthermore, TRPV1 antagonists including
AS1928370 and SB-705498 also significantly reduce
complete Freund’s adjuvant-induced or nerve injury-
induced thermal hyperalgesia and mechanical allodynia
[23,25,26]. Upregulated function of TRPV1 is therefore
believed to mediate the sensitization of nociceptive DRG
neurons and cause inflammatory or neuropathic hyper-
algesia [4,18]. Interestingly, CCR2 – the CCL2 receptor –
is found in TRPV1-expressing nociceptive DRG neurons
[15]. A reasonable hypothesis is therefore that upregulated
CCL2 induces pain hypersensitivity within the DRG by
augmenting TRPV1 function in DRG neurons.
The tetrodotoxin (TTX)-resistant Nav1.8 sodium
channel is almost exclusively expressed in small-
diameter nociceptive neurons of the DRG [27-31] and
plays an essential role in the upstroke of action poten-
tials and continuous firing activity of DRG nociceptive
neurons [29,32,33]. Accumulating data indicate that
Nav1.8 expressed in nociceptive sensory neurons is not
only involved in normal pain sensation but also plays an
important role in inflammatory and neuropathic pain
[29-31]. A decrease in behavioral responses to noxious
thermal and mechanical stimulus as well as delayed in-
flammatory hyperalgesia were observed in Nav1.8 knock-
out mice [34]. Knockdown of Nav1.8 expression in the
DRG by anti-sense oligodeoxynucleotides attenuated
mechanical allodynia and thermal hyperalgesia caused
by peripheral inflammation and nerve injury [35,36].
Peripheral inflammation or nerve injury has been shown
to upregulate mRNA expression of Nav1.8 in nociceptive
DRG neurons [37-39]. Furthermore, A-803467, a potent
and selective Nav1.8 sodium channel blocker, inhibited
nerve injury-induced mechanical allodynia and
inflammation-induced thermal hyperalgesia [40]. Both
CCR2 and Nav1.8 are found in small nociceptive DRG
neurons [15,27,28]. CCL2 is therefore likely to cause
pain hypersensitivity of nociceptive DRG neurons by
upregulating the function of Nav1.8 sodium channels.
TRPV1 channels and TTX-resistant Nav1.8 channels
are two major regulators of excitability and pain trans-
mission in small-diameter nociceptive DRG neurons
[18-20,29,30,33]. Following tissue inflammation or nerve
injury, an elevated CCL2 level within the DRG could very
probably cause peripheral sensitization of nociceptive
DRG neurons and hyperalgesia by upregulating the
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function of TRPV1 channels and Nav1.8 sodium channels
in DRG nociceptive neurons. In accordance with this
hypothesis, the present study showed that CCL2 pretreat-
ment significantly increased the current density of TRPV1
agonist capsaicin-evoked inward currents and TTX-
resistant sodium currents in cultured small-diameter DRG
neurons by upregulating mRNA expression of TRPV1
channels and Nav1.8 sodium channels, respectively.
Methods
Chemicals and reagents
DMEM/F12 and fetal bovine serum were purchased
from GIBCO Life Technologies (Carlsbad, CA, USA).
Recombinant rat CCL2 was obtained from R&D Systems
(Minneapolis, MN, USA). Capsaicin, tetrodotoxin, CCR2
antagonist BMS CCR2 22, phosphatidylinositol-3 kinase
(PI3K) inhibitor LY294002 and ERK 1/2 inhibitor U0126
were from Tocris Bioscience (Bristol, UK). Akt inhibitor
IV was purchased from Calbiochem (Darmstadt,
Germany). Trizol for RNA isolation and cDNA synthesis
reagents were obtained from Invitrogen (Carlsbad, CA,
USA). The SYBR Green PCR Master Mix kit was pur-
chased from Applied Biosystems (Foster City, CA, USA).
Primary neuronal culture of the dorsal root ganglion
Animals were handled according to protocols approved
by the Animal Care and Use Committee of Chang Gung
University. Three-week-old Sprague–Dawley rats were
terminally anesthetized with sodium pentobarbital and
were decapitated. Lumbar DRGs were dissected and
incubated with DMEM/F12 containing collagenase type
II (3 mg/ml; Sigma, St Louis, MO, USA) for 50 minutes
at 37°C. After being washed, DRGs were further digested
with trypsin (0.3 mg/ml; Sigma) dissolved in DMEM/
F12 for 20 minutes at 37°C. Ganglia were then dispersed
by a fire-polished Pasteur pipette, and dissociated cells
were plated onto poly-L-ornithine-coated and collagen-
coated dishes. DRG neurons were then cultured in
DMEM/F12 supplemented with 10 % heat-inactivated
bovine serum. Proliferation of non-neuronal cells was
prevented by adding 10 μM 5′-fluoro-2′-deoxyuridine
and 10 μM uridine into culture medium. Two-day-old
or 3-day-old cultured DRG neurons were incubated with
different concentrations of CCL2 (R&D Systems) for 24
to 36 hours in the presence of a cocktail of protease
inhibitors (Sigma) and then used for electrophysiological
recordings or RT-PCR assays. For control experiments, a
cocktail of protease inhibitors (Sigma) was added to the
culture medium.
Whole-cell voltage-clamp recording of capsaicin-evoked
currents or tetrodotoxin-resistant sodium currents
Small-diameter DRG neurons were voltage-clamped
using the conventional whole-cell version of patch-
clamp techniques. Patch pipettes with a resistance of 5
MΩ were fabricated from hard borosilicate glasses using
a pipette puller (P-87; Sutter Instruments, Novato, CA,
USA). For the recording of TRPV1 agonist capsaicin-
evoked currents, the extracellular solution had the fol-
lowing composition: NaCl 145 mM, KCl 3 mM, CaCl2
2 mM, MgCl2 1 mM, glucose 12 mM, and HEPES
10 mM (pH 7.3 with NaOH). The patch electrode was
filled with the following: KCl 35 mM, KF 100 mM,
MgCl2 1 mM, EGTA 5 mM, ATP 2 mM and HEPES
10 mM (pH 7.3 with KOH). A stock solution (5 mM) of
capsaicin was made in ethanol and diluted in the exter-
nal solution. Capsaicin was applied to DRG neurons
using the fast perfusion SF77-B system (Warner Instru-
ments, Hamden, CT, USA). To record TTX-resistant so-
dium currents, the external solution had the following
composition: NaCl 140 mM, TEA-Cl 10 mM, CoCl2
2 mM, MgCl2 1 mM, glucose 12 mM, TTX 0.0005 mM
and HEPES 10 mM (pH 7.3 with NaOH). The patch
pipette was filled with the solution containing the fol-
lowing: CsCl 140 mM, MgCl2 1 mM, EGTA 5 mM, ATP
2 mM and HEPES 10 mM (pH 7.2 with CsOH).
The membrane current or voltage recorded by the
patch-clamp amplifier (Axopatch-200B; Axon Instru-
ments, Sunnyvale, CA, USA) was filtered, digitized
(Digidata 1200; Axon Instruments) and stored for later
analysis. Liquid junction potentials were corrected, and
the compensation circuitry of the amplifier was used to
minimize the series resistance error. Holding potentials,
data acquisition and data analysis were controlled by
software pCLAMP 7.0 (Axon Instruments). The Prism
program (GraphPad Software) was used to analyze the
dose–response curve. Whole-cell patch-clamp record-
ings were performed at room temperature (24 to 25°C).
Quantitative real-time RT-PCR assay
According to our previous study [41], Trizol reagent
(Invitrogen) was used to prepare total RNA from cul-
tured DRG neurons. Subsequently, the first-strand
cDNA was synthesized in a reaction mixture containing
total RNA (2 μg), 8 ng/μl oligodT primer, 1 mM each
dNTP, 20 U ribonuclease inhibitor and 200 U Super-
Script III RT (Invitrogen). The reaction was performed
for 1 hour at 50°C and was terminated by incubating for
15 minutes at 70°C. Real-time PCR was carried out in
the StepOne Real-Time PCR system (Applied Biosys-
tems) using the SYBR Green PCR Master Mix (Applied
Biosystems). The reaction mixture (40 μl) consisted of a
cDNA aliquot, 400 nM forward or reverse primer and
1× SYBR Green PCR Master Mix containing AmpliTaq
Gold DNA polymerase and SYBR Green 1 dye. The fol-
lowing primers were used for real-time PCR reactions:
CCR2, 5′-GTTGGTGAGAAGTTCCGAAGGT-3′ and
5′-GGTCTGCTGTCTCCCTATAGAA-3′; TRPV1, 5′-
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TTTCAGGGTGGACGAGGTAAA-3′ and 5′-TGCCTG
GGTCCTCGTTGA-3′; α subunit of Nav1.8, 5′-CCGG
TGGAAGCAGGAAGA-3′ and 5′-AGGAGCGGTGCA
GCATGTA-3′; and α subunit of Nav1.9, 5′-TGGA
CTTGCCCATGGTGAT-3′ and 5′-GGACCCTGGTAG
TGAAAGCAAA-3′. PCR amplification was performed
for 10 minutes at 95°C and was followed by 40 cycles of
15 seconds at 95°C and 1 minute at 60°C. PCR amplifica-
tion of GAPDH mRNA was used as the normalization
control. The relative change in mRNA expressions
was determined by the equation: Fold change ¼ 2½ΔΔCt;
ΔΔCt ¼ ðCtCCR2=TRPV1=Nav:1:8=Nav1:9  CtGAPDHÞCCL2 
ðCtCCR2=TRPV1=Nav1:8=Nav1:9  CtGAPDHÞcontrol where Ct value
is the cycle number at which the fluorescence signal crosses
the threshold.
Statistical analysis
Results are expressed as the mean ± standard error value
of n experiments. Statistical significance among multiple
experimental groups was determined by one-way ana-
lysis of variance followed by Dunnett’s test. An unpaired
Student’s t test (two-tailed) was used to determine the
significant difference between two groups of data. P
<0.05 was considered significant.
Results
Chemokine CCL2 augments TRPV1 agonist
capsaicin-evoked currents in small-diameter DRG neurons
and upregulates mRNA expression of TRPV1 in cultured
DRG neurons
In the present study, we hypothesized that, during in-
flammatory or neuropathic pain, upregulated chemokine
CCL2 induces hyperactivity of DRG nociceptive neurons
and hyperalgesia by directly enhancing the function of
TRPV1. To test this hypothesis, an in vitro inflammatory
model of CCL2 upregulation in the DRG was prepared
by pretreating primary culture of rat DRG neurons with
different concentrations of CCL2 for 24 to 36 hours.
According to a previous study [42], our in vitro inflam-
matory model was also believed to cause activity-
dependent upregulation of CCR2 expression in DRG
neurons. Consistent with this hypothesis, real-time
RT-PCR assays demonstrated that pretreating cultured
DRG neurons with 5 nM CCL2 for 24 to 36 hours
induced a 3.2 ± 0.3-fold increase (n= 4 experiments) in
the mRNA level of CCR2. Subsequently, TRPV1 agonist
capsaicin-evoked inward cationic currents were recorded
from control or CCL2-treated DRG sensory neurons
(Figure 1).
According to the general belief that TRPV1 is mainly
expressed in small-diameter DRG cells, which are
believed to function as nociceptive neurons [19,20,43],
cultured small DRG neurons (diameter = 15 to 20 μm)
were selected for whole-cell patch-clamp recordings.
The mean resting membrane potential, membrane cap-
acitance and input resistance of control small-diameter
DRG neurons were −59 ± 3 mV, 22 ± 3 pF and 520 ± 36
MΩ, respectively (n= 25). CCL2 (5 nM) pretreatment
for 24 to 36 hours did not significantly affect the resting
membrane potential (−55 ± 2 mV; n= 25), membrane
capacitance (23 ± 3 pF) and input resistance (495 ± 25
MΩ) of small DRG sensory neurons. In accordance with
previous studies [6,7], whole-cell current-clamp record-
ing showed that application of 10 nM CCL2 induced a
membrane depolarization (6 ± 1 mV; n= 8) from CCL2-
pretreated cultured small DRG neurons.
Application of TRPV1 agonist capsaicin dose-
dependently evoked inward cationic currents from
Figure 1 CCL2 pretreatment augments capsaicin-evoked
inward cationic currents in small-diameter dorsal root ganglion
neurons. (A) Compared with capsaicin (0.3 μM)-induced inward
cationic current in a control small dorsal root ganglion (DRG)
sensory neuron, the amplitude of capsaicin-evoked inward current
was greatly increased in a small-diameter DRG neuron preincubated
with 5 nM chemokine CC chemokine ligand 2 (CCL2) for 24 hours.
Holding potential (VH) =−60 mV. (B) CCL2 pretreatment increased
the density of capsaicin (0.3 μM)-induced inward currents with a
concentration-dependent manner. Each point shows the mean ±
standard error value of 10 neurons.
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small-diameter putative DRG nociceptive neurons at the
holding potential of −60 mV (EC50 value = 0.5 ± 0.04 μM;
Figures 1 and 2A). Following the preincubation of CCL2
(5 nM) for 24 to 36 hours, the mean amplitude of capsa-
icin (0.3 μM)-evoked cationic current was greatly
increased in small-diameter DRG neurons (Figure 1A;
control density of capsaicin current = 20 ± 2 pA/pF; with
CCL2 pretreatment, density of capsaicin current = 42 ± 4
pA/pF; n= 12; holding potential =−60 mV). CCL2
pretreatment increased the density of capsaicin
(0.3 μM)-induced current in a concentration-dependent
manner (EC50 value = 0.6 ± 0.05 nM; Figure 1B). In the
presence of the potent and specific CCR2 antagonist
BMS CCR2 22 (0.5 μM) [44], CCL2 (5 nM) pretreatment
failed to significantly increase the magnitude of capsaicin
(0.3 μM)-evoked currents in small DRG sensory neurons
(control density of capsaicin current = 21 ± 2 pA/pF; with
CCL2 and BMS CCR2 22, density of capsaicin current =
23 ± 3 pA/pF; n= 5; holding potential =−60 mV).
Pretreating DRG neurons with 5 nM CCL2 for 24 to
36 hours increased the maximal magnitude of capsaicin-
evoked inward currents without significantly affecting
the EC50 value (control EC50 value = 0.5 ± 0.04 μM; with
5 nM CCL2 pretreatment, EC50 value = 0.6 ± 0.05 μM;
Figure 2A). CCL2 is therefore not likely to augment cap-
saicin activation of TRPV1 by enhancing capsaicin affin-
ity for TRPV1 channels. Instead, it is very likely that
CCL2 increases the density of capsaicin-evoked inward
currents by upregulating the expression level of TRPV1
in DRG sensory neurons. Consistent with this hypoth-
esis, real-time RT-PCR assays demonstrated that, com-
pared with control cultured DRG neurons, the mRNA
level of TRPV1 was greatly increased in DRG sensory
neurons pretreated with 5 nM CCL2 for 24 to 36 hours
(Figure 2B). Our results strongly suggest that CCL2 aug-
ments TRPV1 function and enhances nociceptive trans-
mission of small-diameter DRG neurons by upregulating
TRPV1 mRNA expression.
CCL2 augments capsaicin activation of TRPV1 and
increases the TRPV1 mRNA level through activating the
PI3K/Akt pathway
CCL2 activation of CCR2 has been shown to produce
various cellular responses via two signal transduction
pathways, the PI3K/Akt and ERK 1/2 cascades [45-48].
LY294002, a specific PI3K inhibitor [49,50], was used to
test the involvement of PI3K in mediating CCL2 (5 nM)
potentiation of capsaicin-evoked inward currents. In the
presence of 10 μM LY294002, CCL2 pretreatment failed
to increase the amplitude of capsaicin (0.3 μM)-evoked
inward currents in small-diameter DRG neurons
(Figure 3A,B). On the other hand, U0126 (20 μM) – a
potent and specific inhibitor of ERK 1/2 – failed to affect
CCL2 enhancement of capsaicin-induced inward cur-
rents in small DRG sensory neurons (Figure 3A,B). RT-
PCR assays further demonstrated that LY294002 almost
completely inhibited CCL2 upregulation of TRPV1
mRNA expression in DRG sensory neurons (Figure 3C).
Akt/protein kinase B (PKB) is a critical downstream
target of PI3K and mediates various PI3K-dependent
signal pathways via phosphorylating target proteins
[51,52]. The possible role of Akt/PKB in mediating
CCL2 enhancement of capsaicin activation of TRPV1
Figure 2 CCL2 increases density of capsaicin-evoked inward
currents by upregulating TRPV1 mRNA expression in sensory
neurons. (A) The concentration–response curve for the density of
capsaicin-induced inward currents was obtained from small-
diameter dorsal root ganglion (DRG) neurons in the absence and
presence of chemokine CC chemokine ligand 2 (CCL2; 5 nM)
pretreatment. Note that CCL2 preincubation increased the density of
capsaicin currents without significantly affecting the EC50 value.
Holding potential (VH) =−60 mV. Each point represents the mean ±
standard error (SE) value of 12 neurons. (B) Quantitative RT-PCR
assays showed that pretreating cultured DRG neurons with 5 nM
CCL2 for 24 to 36 hours greatly increased the mRNA level of
transient receptor potential vanilloid receptor 1 (TRPV1). Each bar
shows the mean ± SE value of five experiments. *P <0.01.
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cation channels was investigated using the Akt/PKB-spe-
cific inhibitor Akt inhibitor IV (1 μM) [49,50,53]. Pre-
treating cultured DRG neurons with CCL2 (5 nM) and
Akt inhibitor IV for 24 to 36 hours did not significantly
augment the magnitude of capsaicin-evoked inward cur-
rents (Figure 4A,B). RT-PCR assays also showed that
Akt inhibitor IV completely blocked CCL2-induced
upregulation of TRPV1 mRNA expression in cultured
DRG neurons (Figure 4C). Our results suggest that
CCL2 upregulates the expression and function of TRPV1
and facilitates nociceptive transmission of DRG sensory
neurons by activating the PI3K/Akt signaling pathway.
CCL2 increases the density of TTX-resistant sodium
currents in small-diameter DRG neurons and the Nav1.8
mRNA level in cultured DRG neurons
To test the hypothesis that CCL2 enhances the
excitability of DRG nociceptive neurons and causes
hyperalgesia by augmenting TTX-resistant sodium cur-
rents, we recorded TTX-insensitive Na+ currents of
small-diameter DRG neurons in the presence of 0.5 μM
TTX. The membrane potential of small DRG sensory
neurons was held at −80 mV, and depolarizing steps (50
milliseconds) from −50 mV to 50 mV were applied to
cause the opening of TTX-resistant sodium channels
(Figure 5A). In the present study, slowly inactivating
TTX-insensitive Na+ currents of small-diameter DRG
neurons displayed activation threshold of approximately
−40 mV and peak amplitude at about −20 to −10 mV
(Figure 5A,B). These electrophysiological properties are
similar to those of TTX-resistant Nav1.8 sodium chan-
nels [27,29,34]. In addition to Nav1.8, Nav1.9 is another
subtype of TTX-insensitive Na+ channels expressed in
small-diameter DRG nociceptive neurons [29,31,54].
Nav1.8 current is believed to be the major TTX-resistant
sodium current recorded from small DRG sensory neu-
rons [29,54-56]. Previous studies also reported that
Nav1.9 currents exhibited the phenomenon of washout
and that the magnitude of Nav1.9 current is quite small
with chloride-based internal solution used in the present
study [29,55-57]. As a result, we failed to record TTX-
insensitive Nav1.9 currents, which have a lower
Figure 3 CCL2 augments capsaicin-evoked inward currents and
increases TRPV1 mRNA in neurons via activating
phosphatidylinositol-3 kinase. (A) Following co-treating cultured
dorsal root ganglion (DRG) neurons with chemokine CC chemokine
ligand 2 (CCL2) (5 nM) and phosphatidylinositol-3 kinase (PI3K)
inhibitor LY294002 (10 μM) for 24 to 36 hours, CCL2 failed to
significantly enhance the amplitude of capsaicin (0.3 μM)-evoked
inward current in a small-diameter DRG neuron. In the presence of
ERK 1/2 inhibitor U0126 (20 μM), CCL2 still greatly augmented the
magnitude of capsaicin currents in a small DRG sensory neuron.
Holding potential (VH) =−60 mV. (B) Pretreating small-diameter DRG
neurons with 5 nM CCL2 significantly increased the density of
capsaicin-evoked inward currents. LY294002 (10 μM) almost
completely blocked CCL2 enhancement of capsaicin currents, and
U0126 (20 μM) failed to affect CCL2 potentiation of capsaicin
currents. Each bar shows the mean± standard error (SE) value of 10
to 13 neurons. (C) RT-PCR assays showed that CCL2 (5 nM)
pretreatment significantly increased the transient receptor potential
vanilloid receptor 1 (TRPV1) mRNA level of cultured DRG neurons. In
the presence of 10 μM LY294002, CCL2 pretreatment of DRG
sensory neurons for 24 to 36 hours failed to upregulate TRPV1
mRNA expression. Each bar represents the mean± SE value of five
experiments. *P <0.01 compared with control neurons.
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threshold of activation (−60 mV to −70 mV) and are
persistent sodium currents [58,59], from cultured small
DRG sensory neurons prepared in the present study
(Figure 5). The TTX-resistant Na+ currents of small-
diameter DRG neurons we recorded therefore predom-
inantly result from the opening of Nav1.8 channels.
The current–voltage curves of TTX-insensitive sodium
currents showed that, compared with control small DRG
sensory neurons, the density of TTX-resistant Na+
currents at all step potentials was significantly increased
in small-diameter DRG neurons pretreated with 5 nM
CCL2 for 24 to 36 hours (Figure 5A,B). Pretreating small
DRG sensory neurons with CCL2 increased the density of
TTX-resistant sodium currents with a concentration-
dependent manner (EC50 value=0.7± 0.06 nM; Figure 5C).
In the presence of the potent and specific CCR2 antagonist
BMS CCR2 22 (0.5 μM) [44], 5 nM CCL2 pretreatment
failed to significantly increase the density of TTX-
insensitive Na+ currents in small DRG sensory neurons
(control density of TTX-resistant Na+ currents at −10 mV=
47±3 pA/pF; with CCL2 and BMS CCR2 22, density of
TTX-insensitive Na+ currents=51±5 pA/pF; n=5). CCL2
pretreatment did not significantly affect the threshold po-
tential for activation, the step potential for peak value and
the inactivation kinetics of Nav1.8-mediated TTX-
insensitive sodium currents (Figure 5A,B). These results
suggest that CCL2 increases the magnitude of TTX-
insensitive Na+ currents by upregulating the expression of
Nav1.8. In accordance with this hypothesis, real-time RT-
PCR assays demonstrated that, compared with control
DRG neurons, the mRNA level of Nav1.8 was significantly
increased in DRG neurons pretreated with 5 nM CCL2 for
24 to 36 hours (Figure 5D). On the contrary, CCL2 pre-
treatment did not affect the mRNA level of TTX-resistant
Nav1.9 in cultured DRG neurons (Figure 5D).
CCL2 upregulates the density of TTX-resistant sodium
currents and Nav1.8 mRNA expression by activating the
PI3K/Akt pathway
CCL2 probably increases the magnitude of TTX-
insensitive Na+ currents and upregulates Nav1.8 mRNA
expression via one of two CCL2-activated signaling path-
ways, the PI3K/Akt and ERK 1/2 cascades. In the pres-
ence of ERK 1/2 inhibitor U0126 (20 μM), CCL2 (5 nM)
pretreatment still augmented the amplitude of TTX-
resistant sodium currents in small DRG sensory neurons
(Figure 6A,B). Co-treating cultured DRG neurons with
CCL2 and PI3K inhibitor LY294002 (10 μM) almost
completely blocked CCL2 enhancement of TTX-
insensitive Na+ currents in small-diameter DRG neurons
(Figure 6A,B). In the presence of Akt inhibitor IV
(1 μM), CCL2 preincubation also failed to increase the
magnitude of TTX-resistant sodium currents in small
DRG sensory neurons (Figure 6A,B). Consistent with the
results of whole-cell voltage-clamp recordings, real-time
RT-PCR assays showed that co-treatment of LY294002
or Akt inhibitor IV greatly inhibited CCL2-induced upre-
gulation of Nav1.8 mRNA expression in DRG sensory
Figure 4 CCL2 enhances capsaicin currents and upregulates
TRPV1 mRNA expression in neurons via activating Akt. (A) In
the presence of Akt inhibitor IV (1 μM), chemokine CC chemokine
ligand 2 (CCL2) (5 nM) pretreatment did not augment the
magnitude of capsaicin (0.3 μM)-evoked inward current. Holding
potential (VH) =−60 mV. (B) Akt inhibitor IV significantly blocked
CCL2 upregulation of density of capsaicin currents. Each bar shows
the mean± standard error (SE) value of 10 neurons. (C) CCL2
pretreatment of dorsal root ganglion (DRG) neurons for 24 to 36
hours failed to increase transient receptor potential vanilloid
receptor 1 (TRPV1) mRNA level in the presence of 1 μM Akt inhibitor
IV. Each bar represents the mean± SE value of five experiments.
*P <0.01 compared with control neurons.
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neurons (Figure 6C). These results suggest that CCL2
upregulates the expression and function of Nav1.8 chan-
nels and enhances the excitability of small DRG nocicep-
tive neurons via the activating PI3K/Akt pathway.
Discussion
Chronic inflammatory or neuropathic pain is associated
with sensory disturbances characterized by hyperalgesia,
allodynia and spontaneous pain [3,4,60]. Previous studies
using animal models of inflammatory or neuropathic
pain demonstrated that expression levels of CCL2 and
its receptor CCR2 were upregulated in neuronal and
glial cells of DRG [8-14]. Tissue inflammation-induced
or nerve injury-induced upregulation and release of
CCL2 within the DRG could therefore facilitate nocicep-
tive processing by DRG sensory neurons and resulting
hyperalgesia [1-3,5,16]. The exact molecular mechanism
by which CCL2 enhances the excitability of DRG sensory
neurons and induces the resulting pain hypersensitivity
remains unknown.
Noxious stimuli-induced activation of TRPV1, a
nonselective cation channel selectively expressed in
nociceptive DRG neurons, induces inward cationic
currents and action potentials, which then convey noci-
ceptive information to spinal dorsal horn [18-20]. Per-
ipheral inflammation or neuropathy upregulated TRPV1
expression in DRG nociceptive neurons [21-24], and
knockdown of TRPV1 expression or TRPV1 antagonists
significantly inhibited inflammation-induced or nerve
injury-induced thermal hyperalgesia and mechanical
allodynia [22,23,25,26]. CCR2 and TRPV1 are co-
expressed in small DRG nociceptive neurons [15]. We
therefore hypothesized that upregulated CCL2 facilitates
nociceptive transmission of DRG sensory neurons by po-
tentiating TRPV1 function in DRG sensory neurons. To
test this hypothesis, we recorded TRPV1 agonist
Figure 5 CCL2 increases the density of tetrodotoxin-resistant sodium currents in small dorsal root ganglion sensory neurons. (A) In the
presence of 0.5 μM tetrodotoxin (TTX), the holding potential (VH) of small dorsal root ganglion (DRG) sensory neurons was held at −80 mV, and
depolarizing steps (50 milliseconds) were applied from −50 mV to 50 mV with an increment of 10 mV. The I–V (current–voltage) curve of TTX-
insensitive Na+ currents was then obtained from control or chemokine CC chemokine ligand 2 (CCL2; 5 nM)-pretreated small-diameter DRG
neurons. Each point represents the mean± standard error (SE) value of 10 neurons. (B) Traces of TTX-resistant sodium currents were evoked from
a VH of −80 mV to step potentials ranging from −20 mV to 20 mV. Compared with a control small DRG sensory neuron, the magnitude of TTX-
insensitive Na+ currents was greatly increased in a CCL2-pretreated small-diameter DRG neuron. (C) CCL2 pretreatment increased the density of
TTX-resistant sodium currents recorded at −10 mV in a dose-dependent manner. Each point shows the mean ± SE value of eight neurons. (D)
Pretreating cultured DRG neurons with 5 nM CCL2 for 24 to 36 hours significantly upregulated mRNA expression of Nav1.8 without affecting the
Nav1.9 mRNA level. Each bar represents the mean± SE value of five experiments. *P <0.01 compared with control neurons.
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capsaicin-evoked inward cationic currents from control
or CCL2-preincubated small putative DRG nociceptive
neurons. CCL2 pretreatment dose-dependently upregu-
lated the density of capsaicin-induced currents by in-
creasing the mRNA level of TRPV1 in DRG sensory
neurons. This finding strongly suggests that CCL2
enhances TRPV1 function and facilitates nociceptive
transmission of small-diameter DRG nociceptive neu-
rons by upregulating the expression of TRPV1. Interest-
ingly, chemokine CCL3 is believed to cause
inflammatory hyperalgesia by potentiating capsaicin-
gated TRPV1 channel activity in DRG nociceptive
neurons [61]. Cytokine TNFα has also been shown to
augment capsaicin-evoked response in DRG or trigminal
sensory neurons by upregulating TRPV1 expression
[62,63]. Together with our results reported here, these
results suggest that upregulated expression and function
of TRPV1 is one of common pathogenic mechanisms by
which proinflammatory cytokines or chemokines induce
the peripheral sensitization of DRG nociceptive neurons
and cause inflammatory or neuropathic hyperalgesia.
The expression of TTX-insensitive Nav1.8 is mainly
restricted to small DRG nociceptive neurons [27-31],
and opening of Nav1.8 channels contributes to the up-
stroke of action potential and continuous discharge of
DRG nociceptive neurons [32,33]. Upregulated mRNA
expression of Nav1.8 was observed in DRG sensory neu-
rons following peripheral inflammation or nerve injury
[37-39], and knockdown of Nav1.8 expression or Nav1.8
sodium channel blocker blocked nerve injury-induced or
inflammation-induced hyperalgesia [35,36,40]. CCR2
and Nav1.8 are co-expressed in small nociceptive DRG
neurons [15,28]. We therefore hypothesized that CCL2
causes hyperactivity of DRG nociceptive neurons and
hyperalgesia by upregulating the function of Nav1.8 and
enhancing the membrane excitability of DRG sensory
neurons. Consistent with this hypothesis, pretreating
small-diameter DRG nociceptive neurons with CCL2
significantly increased the current density of Nav1.8-
mediated TTX-resistant Na+ currents without affecting
the activation threshold or kinetic properties. Further
real-time RT-PCR assays demonstrated that CCL2 sig-
nificantly upregulated Nav1.8 mRNA expression in DRG
sensory neurons. These results propose that following
tissue inflammation or peripheral nerve injury,
Figure 6 CCL2 increases tetrodotoxin-resistant Na+ current
amplitude and Nav1.8 mRNA through activating the
phosphatidylinositol-3 kinase/Akt pathway. (A) Tetrodotoxin
(TTX)-insensitive sodium currents were evoked from a holding
potential (VH) of −80 mV to step potentials ranging from −20 mV to
20 mV. In the presence of ERK 1/2 inhibitor U0126 (20 μM),
chemokine CC chemokine ligand 2 (CCL2) preincubation greatly
increased the magnitude of TTX-resistant Na+ currents in a small
dorsal root ganglion (DRG) sensory neuron. Pretreating small-
diameter DRG neurons with 5 nM CCL2 did not augment the
amplitude of TTX-resistant sodium currents in the presence of
phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 (10 μM) or
Akt inhibitor IV (1 μM). (B) Pretreating small-diameter DRG neurons
with 5 nM CCL2 increased the density of TTX-insensitive sodium Na+
currents recorded at −20 mV. PI3K inhibitor LY294002 or Akt
inhibitor IV almost completely inhibited CCL2 enhancement of TTX-
resistant Na+ currents. Each bar shows the mean ± standard error
(SE) value of 10 neurons. (C) Pretreating DRG neurons with 5 nM
CCL2 for 24 to 36 hours significantly increased the mRNA level of
Nav1.8. PI3K inhibitor LY294002 or Akt inhibitor IV significantly
inhibited CCL2 upregulation of Nav1.8 mRNA expression. Each bar
represents the mean ± SE value of five experiments. *P <0.01
compared with control neurons.
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upregulation of expression and current density of Nav1.8
caused by CCL2 and other proinflammatory cytokines
or chemokines augments the membrane excitability and
induces ectopic discharges of DRG sensory neurons,
leading to the development of inflammatory or neuro-
pathic pain. In accordance with our hypothesis, chemo-
kine CXCL1 has been shown to increase the current
density of TTX-resistant currents and the mRNA level
of Nav1.8 in small-diameter DRG sensory neurons [57].
Following the nerve injury, TNFα also increased the
amplitude of TTX-insensitive sodium currents in DRG
nociceptive neurons by upregulating mRNA expression
of Nav1.8 [38,39].
Our results suggest that an elevated CCL2 level fol-
lowing tissue inflammation or nerve injury could cause
peripheral sensitization of DRG nociceptive neurons and
hyperalgesia by upregulating the expression and function
of TRPV1 channels and Nav1.8 sodium channels. CCL2
has been shown to produce various cellular responses
via two signal transduction pathways, the PI3K/Akt and
ERK 1/2 cascades [45-48]. U0126, a potent and specific
inhibitor of ERK 1/2, failed to block CCL2 enhancement
of capsaicin-induced inward currents and TTX-resistant
sodium currents in small DRG sensory neurons. In the
presence of the specific PI3K inhibitor LY294002, CCL2
pretreatment failed to increase the current density of
capsaicin-evoked inward currents or TTX-insensitive Na
+ currents and the mRNA level of TRPV1 or Nav1.8.
Specific Akt/PKB inhibitor IV also almost completely
blocked CCL2-induced enhancement of capsaicin-
evoked currents or TTX-resistant sodium currents and
upregulation of TRPV1 or Nav1.8 mRNA expression.
These results strongly suggest that CCL2 upregulates
the expression and function of TRPV1 or Nav1.8 chan-
nels and enhances membrane excitability and nocicep-
tive transmission of DRG sensory neurons via activating
the PI3K/Akt signaling pathway. Consistent with our
results, several lines of evidence suggested that activa-
tion of the PI3K/Akt pathway is involved in peripheral
sensitization of DRG nociceptive neurons and subse-
quent development of inflammatory or neuropathic pain
[64]. PI3K and Akt are expressed in small DRG nocicep-
tive neurons, and the expression of active phospho-Akt
in nociceptive DRG neurons is upregulated in the rat
model of inflammatory or neuropathic pain [49,53,65].
Administration of PI3K inhibitor LY294002 and Akt in-
hibitor IV also inhibited capsaicin-induced or nerve
growth factor-induced hyperalgesia and pain hypersensi-
tivity observed in the animal model of neuropathic pain
[49,53,66].
A previous study reported that brief pretreatment of
monocyte chemoattractant protein-1/CCL2 caused
sensitization of the capsaicin-evoked increase in the
intracellular Ca2+ level in DRG sensory neurons [15].
Monocyte chemoattractant protein-1/CCL2-induced
sensitization or transactivation of TRPV1 channels,
which is mediated by phospholipase C and protein kin-
ase C signaling pathways [15], could enhance the func-
tion of TRPV1 channels and cause pain hypersensitivity.
During an in vivo pathological condition of tissue in-
flammation or peripheral nerve injury, the continuous
presence of a high level of CCL2 should cause both
upregulation of the TRPV1 mRNA level reported in the
present study and transactivation of TRPV1 channels
reported previously [15]. Following tissue inflammation
or peripheral nerve injury, CCL2 therefore probably
enhances the function of TRPV1 channels and facilitates
the nociceptive transmission of DRG nociceptive neu-
rons via two different molecular pathogenic mechan-
isms: PI3K/Akt-mediated upregulation of TRPV1 mRNA
expression, and phospholipase C/protein kinase C-
mediated transactivation of TRPV1 channels.
Akt mediates PI3K-dependent cellular responses via
phosphorylating various target proteins including tran-
scription factors [51,52]. The CCL2-activated PI3K/Akt
pathway therefore probably increases the mRNA level of
TRPV1 or Nav1.8 in DRG sensory neurons by enhancing
the transcription of TRPV1 or the Nav1.8 gene. Func-
tional promoter analysis indicated that the neuron-
specific proximal promoter region of the Nav1.8 gene
expressed in rat DRG neurons contained putative bind-
ing sites for transcription factor SP1 [67]. A recent
chromatin immunoprecipitation analysis of DRG tissue
demonstrated that the endogenous TRPV1 P2-promoter
contains GC-box binding sites of transcription factor
Sp1. Overexpression of Sp1 in cultured DRG neurons
caused an increase in TRPV1 mRNA, and knockdown of
Sp1 mRNA resulted in a decrease in TRPV1 mRNA
[68]. Transcription factor SP1 therefore plays an import-
ant role in activating TRPV1 or Nav1.8 mRNA transcrip-
tion in DRG sensory neurons. Interestingly, epidermal
growth factor-induced activation of the PI3K/Akt path-
way upregulated the mRNA expression of vascular endo-
thelial growth factor in cell lines through Akt-mediated
phosphorylation of transcription factor Sp1 and subse-
quent increased Sp1 binding to the vascular endothelial
growth factor promoter [69]. Bcl-w-stimulated PI3K/Akt
signaling also caused Sp1 activation and the resulting
increased matrix metalloproteinase-2 expression in gas-
tric adenocarcinoma cell lines [70]. CCL2 activation of
Akt therefore possibly enhances the transcriptional ac-
tivity of TRPV1 or the Nav1.8 gene and increases the
mRNA level of TRPV1 or Nav1.8 by phosphorylating
and activating transcription factor Sp1. Further research
is required to investigate the exact molecular mechanism
by which the CCL2-activated PI3K/Akt pathway upregu-
lates mRNA expression of TRPV1 or Nav1.8 in DRG
sensory neurons.
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Conclusions
In summary, our results demonstrate that CCL2
increased the density of TRPV1 agonist capsaicin-
induced currents and Nav1.8-mediated TTX-resistant
Na+ currents in small putative DRG nociceptive neu-
rons. Further studies showed that CCL2 increased the
function and mRNA level of TRPV1 channels and
Nav1.8 sodium channels in DRG sensory neurons via ac-
tivating the PI3K/Akt signaling pathway. These findings
suggest that, following tissue inflammation or peripheral
nerve injury, upregulation and release of CCL2 within
the DRG could facilitate pain transmission mediated by
nociceptive DRG neurons and could induce hyperalgesia
by upregulating the expression and function of TRPV1
channels and Nav1.8 channels in DRG nociceptive
neurons.
Abbreviations
CCL2: CC chemokine ligand 2; CCR2: Chemokine (C-C motif) receptor 2;
DMEM: Dulbecco's Modified Eagle Medium; DRG: Dorsal root ganglion;
EC50: Half-maximal effective concentration; PCR: Polymerase chain reaction;
PI3K: Phosphatidylinositol-3 kinase; PKB: Protein kinase B; RT: Reverse
transcriptase; TNF: Tumor necrosis factor; TRPV1: Transient receptor potential
vanilloid receptor 1; TTX: Tetrodotoxin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
H-LW, AHL, J-CC and R-SL designed the study. D-JK, AHL, Y-LC and J-CL
performed the experiments. H-LW, D-JK, AHL, J-CC and R-SL discussed the
results and prepared the manuscript. All authors read and approved the final
version of this manuscript.
Acknowledgments
This work was supported by the Chang Gung Medical Research Project
(CMRPD150362 and CMRPD150363).
Author details
1Department of Physiology and Pharmacology, Chang Gung University
School of Medicine, Kwei-San, 259 Wen-Hwa 1 road, Tao-Yuan 333, Taiwan.
2Department of Anesthesiology, Chang Gung Memorial Hospital, Kwei-San, 5
Fu-Shing St, Tao-Yuan, 333, Taiwan. 3Department of Neurology, Chang Gung
Memorial Hospital, Kwei-San, 5 Fu-Shing St, Tao-Yuan 333, Taiwan. 4Chang
Gung University of Science and Technology, Kwei-San, 261 Wen-Hwa 1 road,
Tao-Yuan 333, Taiwan.
Received: 26 January 2012 Accepted: 2 July 2012
Published: 8 August 2012
References
1. Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White
FA: Chemokines and pain mechanisms. Brain Res Rev 2009, 60:125–135.
2. Miller RJ, Jung H, Bhangoo SK, White FA: Cytokine and chemokine
regulation of sensory neuron function. Handb Exp Pharmacol 2009,
194:417–449.
3. Gao YJ, Ji RR: Chemokines, neuronal–glial interactions, and central
processing of neuropathic pain. Pharmacol Ther 2010, 126:56–68.
4. Ren K, Dubner R: Interactions between the immune and nervous systems
in pain. Nat Med 2010, 16:1267–1276.
5. White FA, Wilson N: Chemokines as pain mediators and modulators.
Curr Opin Anaesthesiol 2008, 21:580–585.
6. Sun JH, Yang B, Donnelly DF, Ma C, LaMotte RH: MCP-1 enhances
excitability of nociceptive neurons in chronically compressed dorsal root
ganglia. J Neurophysiol 2006, 96:2189–2199.
7. Wang CH, Zou LJ, Zhang YL, Jiao YF, Sun JH: The excitatory effects of the
chemokine CCL2 on DRG somata are greater after an injury of the
ganglion than after an injury of the spinal or peripheral nerve. Neurosci
Lett 2010, 475:48–52.
8. Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK,
Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK,
DeMartino JA, MacIntyre DE, Forrest MJ: Impaired neuropathic pain
responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad
Sci U S A 2003, 100:7947–7952.
9. Tanaka T, Minami M, Nakagawa T, Satoh M: Enhanced production of
monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat
model of neuropathic pain: possible involvement in the development of
neuropathic pain. Neurosci Res 2004, 48:463–469.
10. White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, White FA, Sun J, Waters
SM, Ma C, Ren D, Ripsch M, Steflik J, Cortright DN, Lamotte RH, Miller RJ:
Excitatory monocyte chemoattractant protein-1 signaling is up-regulated
in sensory neurons after chronic compression of the dorsal root
ganglion. Proc Natl Acad Sci U S A 2005, 102:14092–14097.
11. Zhang J, De Koninck Y: Spatial and temporal relationship between
monocyte chemoattractant protein-1 expression and spinal glial activation
following peripheral nerve injury. J Neurochem 2006, 97:772–783.
12. Bhangoo S, Ren D, Miller RJ, Henry KJ, Lineswala J, Hamdouchi C, Bhangoo
S, Ren D, Miller RJ, Henry KJ, Lineswala J, Hamdouchi C, Li B, Monahan PE,
Chan DM, Ripsch MS, White FA: Delayed functional expression of
neuronal chemokine receptors following focal nerve demyelination in
the rat: a mechanism for the development of chronic sensitization of
peripheral nociceptors. Mol Pain 2007, 3:38.
13. Jeon SM, Lee KM, Park ES, Jeon YH, Cho HJ: Monocyte chemoattractant
protein-1 immunoreactivity in sensory ganglia and hindpaw after
adjuvant injection. Neuroreport 2008, 19:183–186.
14. Jung H, Bhangoo S, Banisadr G, Freitag C, Ren D, White FA, Jung H,
Bhangoo S, Banisadr G, Freitag C, Ren D, White FA, Miller RJ: Visualization
of chemokine receptor activation in transgenic mice reveals peripheral
activation of CCR2 receptors in states of neuropathic pain. J Neurosci
2009, 29:8051–8062.
15. Jung H, Toth PT, White FA, Miller RJ: Monocyte chemoattractant protein-1
functions as a neuromodulator in dorsal root ganglia neurons.
J Neurochem 2008, 104:254–263.
16. Menetski J, Mistry S, Lu M, Mudgett JS, Ransohoff RM, Demartino JA,
Macintyre DE, et al: Mice overexpressing chemokine ligand 2 (CCL2) in
astrocytes display enhanced nociceptive responses. Neuroscience 2007,
149:706–714.
17. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR,
Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR,
Koltzenburg M, Basbaum AI, Julius D: Impaired nociception and pain
sensation in mice lacking the capsaicin receptor. Science 2000, 288:306–313.
18. Jara-Oseguera A, Simon SA, Rosenbaum T: TRPV1: on the road to pain
relief. Curr Mol Pharmacol 2008, 1:255–269.
19. Basbaum AI, Bautista DM, Scherrer G, Julius D: Cellular and molecular
mechanisms of pain. Cell 2009, 139:267–284.
20. Gold MS, Gebhart GF: Nociceptor sensitization in pain pathogenesis.
Nat Med 2010, 16:1248–1257.
21. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ: p38 MAPK activation by NGF
in primary sensory neurons after inflammation increases TRPV1 levels
and maintains heat hyperalgesia. Neuron 2002, 36:57–68.
22. Kasama K, Kawakubo M, Suzuki T, Nishizawa T, Ishida A, Nakayama J: RNA
interference-mediated knock-down of transient receptor potential
vanilloid 1 prevents forepaw inflammatory hyperalgesia in rat.
Eur J Neurosci 2007, 25:2956–2963.
23. Yu L, Yang F, Luo H, Liu FY, Han JS, Xing GG, Yu L, Yang F, Luo H, Liu FY,
Han JS, Xing GG, Wan Y: The role of TRPV1 in different subtypes of dorsal
root ganglion neurons in rat chronic inflammatory nociception induced
by complete Freund’s adjuvant. Mol Pain 2008, 4:61.
24. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ: Transient
receptor potential vanilloid 1 is essential for cisplatin-induced heat
hyperalgesia in mice. Mol Pain 2010, 6:15.
25. Chizh BA, O’Donnell MB, Napolitano A, Wang J, Brooke AC, Aylott MC, Chizh
BA, O'Donnell MB, Napolitano A, Wang J, Brooke AC, Aylott MC, Bullman JN,
Gray EJ, Lai RY, Williams PM, Appleby JM: The effects of the TRPV1
antagonist SB-705498 on TRPV1 receptor-mediated activity and
inflammatory hyperalgesia in humans. Pain 2007, 132:132–141.
Kao et al. Journal of Neuroinflammation 2012, 9:189 Page 11 of 13
http://www.jneuroinflammation.com/content/9/1/189
26. Watabiki T, Kiso T, Kuramochi T, Yonezawa K, Tsuji N, Kohara A, Watabiki
T, Kiso T, Kuramochi T, Yonezawa K, Tsuji N, Kohara A, Kakimoto S, Aoki
T, Matsuoka N: Amelioration of neuropathic pain by novel transient
receptor potential vanilloid 1 antagonist AS1928370 in rats without
hyperthermic effect. J Pharmacol Exp Ther 2011, 336:743–750.
27. Akopian AN, Sivilotti L, Wood JN: A tetrodotoxin-resistant voltage gated
sodium channel expressed by sensory neurons. Nature 1996,
379:257–262.
28. Djouhri L, Fang X, Okuse K, Wood JN, Berry CM, Lawson S: The TTX-
resistant sodium channel Nav1.8 (SNS/PN3):expression and correlation
with membrane properties in rat nociceptive primary afferent neurons.
J Physiol 2003, 550:739–752.
29. Cummins TR, Sheets PL, Waxman SG: The roles of sodium channels in
nociception: implication for mechanisms of pain. Pain 2007,
131:243–257.
30. Dib-Hajj SD, Binshtokc AM, Cummins TR, Jarvise MF, Samad T, Zimmermann
K: Voltage-gated sodium channels in pain states: role in pathophysiology
and targets for treatment. Brain Res Rev 2009, 60:65–83.
31. Wang W, Gu J, Li YQ, Tao YX: Are voltage-gated sodium channels on the
dorsal root ganglion involved in the development of neuropathic pain?
Mol Pain 2011, 7:16.
32. Renganathan M, Cummins TR, Waxman SG: Contribution of Na(v)1.8
sodium channels to action potential electrogenesis in DRG neurons.
J Neurophysiol 2001, 86:629–640.
33. Momin A, Wood JN: Sensory neuron voltage-gated sodium channels as
analgesic drug targets. Curr Opin Neurobiol 2008, 18:383–388.
34. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J: The
tetrodotoxin-resistant sodium channel SNS has a specialized function in
pain pathways. Nat Neurosci 1999, 2:541–548.
35. Khasar SG, Gold MS, Levine JD: A tetrodotoxin-resistant sodium current
mediates inflammatory pain in the rat. Neurosci Lett 1998, 256:17–20.
36. Joshi SK, Mikusa JP, Hernandez G, Baker S, Shieh CC, Neelands T, Joshi SK,
Mikusa JP, Hernandez G, Baker S, Shieh CC, Neelands T, Zhang XF, Niforatos
W, Kage K, Han P, Krafte D, Faltynek C, Sullivan JP, Jarvis MF, Honore P:
Involvement of the TTX-resistant sodium channel Nav 1.8 in
inflammatory and neuropathic, but not post-operative, pain states. Pain
2006, 123:75–82.
37. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG: Changes in the
expression of tetrodotoxin-sensitive sodium channels within dorsal root
ganglia neurons in inflammatory pain. Pain 2004, 108:237–247.
38. He XH, Zang Y, Chen X, Pang RP, Xu JT, Zhou X, He XH, Zang Y, Chen X,
Pang RP, Xu JT, Zhou X, Wei XH, Li YY, Xin WJ, Qin ZH, Liu XG: TNF-α
contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons
following motor fiber injury. Pain 2010, 151:266–279.
39. Chen X, Pang RP, Shen KF, Zimmermann M, Xin WJ, Li YY, Chen X, Pang RP,
Shen KF, Zimmermann M, Xin WJ, Li YY, Liu XG: TNF-α enhances the
currents of voltage gated sodium channels in uninjured dorsal root
ganglion neurons following motor nerve injury. Exp Neurol 2011,
227:279–286.
40. Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Jarvis MF,
Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll C,
Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S,
Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu
C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A:
A-803467, a potent and selective Nav1.8 sodium channel blocker,
attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad
Sci U S A 2007, 104:8520–8525.
41. Wang HL, Yeh TH, Chou AH, Kuo YL, Luo LJ, He CY: Polyglutamine-
expanded ataxin-7 activates mitochondrial apoptotic pathway of
cerebellar neurons by upregulating Bax and downregulating Bcl-xL. Cell
Signal 2006, 18:541–552.
42. Jung H, Miller RJ: Activation of the nuclear factor of activated T-cells
(NFAT) mediates upregulation of CCR2 chemokine receptors in dorsal
root ganglion (DRG) neurons: a possible mechanism for activity-
dependent transcription in DRG neurons in association with neuropathic
pain. Mol Cell Neurosci 2008, 37:170–177.
43. Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature 2001,
413:203–210.
44. Cherney RJ, Mo R, Meyer DT, Nelson DJ, Lo YC, Yang G, Cherney RJ, Mo R,
Meyer DT, Nelson DJ, Lo YC, Yang G, Scherle PA, Mandlekar S, Wasserman
ZR, Jezak H, Solomon KA, Tebben AJ, Carter PH, Decicco CP: Discovery of
disubstituted cyclohexanes as a new class of CC chemokine receptor 2
antagonists. J Med Chem 2008, 51:721–724.
45. Schecter AD, Berman AB, Yi L, Ma H, Daly CM, Soejima K, Schecter AD,
Berman AB, Yi L, Ma H, Daly CM, Soejima K, Rollins BJ, Charo, Taubman MB:
MCP-1-dependent signaling in CCR2−/− aortic smooth muscle cells.
J Leukoc Biol 2004, 75:1079–1085.
46. Pacheco P, Vieira-de-Abreu A, Gomes RN, Barbosa-Lima G, Wermelinger LB,
Maya-Monteiro CM, Pacheco P, Vieira-de-Abreu A, Gomes RN, Barbosa-Lima
G, Wermelinger LB, Maya-Monteiro CM, Silva AR, Bozza MT, Castro-Faria-
Neto HC, Bandeira-Melo C, Bozza PT: Monocyte chemoattractant protein-
1/CC chemokine ligand 2 controls microtubule-driven biogenesis and
leukotriene B 4-synthesizing function of macrophage lipid bodies
elicited by innate immune response. J Immunol 2007, 179:8500–8508.
47. Webb A, Johnson A, Fortunato M, Platt A, Crabbe T, Christie MI, Webb A,
Johnson A, Fortunato M, Platt A, Crabbe T, Christie MI, Watt GF, Ward SG, Jopling
LA: Evidence for PI-3 K-dependent migration of Th17-polarized cells in
response to CCR2 and CCR6 agonists. J Leukoc Biol 2008, 84:1202–1212.
48. Semple BD, Kossmann T, Morganti-Kossmann MC: Role of chemokines in
CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2
networks. J Cereb Blood Flow Metab 2010, 30:459–473.
49. Xu JT, Tu HY, Xin WJ, Liu XG, Zhang GH, Zhai CH: Activation of
phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root
ganglia and spinal cord contributes to the neuropathic pain induced by
spinal nerve ligation in rats. Exp Neurol 2007, 206:269–279.
50. Choi JI, Svensson CI, Koehrn FJ, Bhuskute A, Sorkin LS: Peripheral
inflammation induces tumor necrosis factor dependent AMPA receptor
trafficking and Akt phosphorylation in spinal cord in addition to pain
behavior. Pain 2010, 149:243–253.
51. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol
3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006,
7:606–619.
52. Franke TF: PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473–6488.
53. Sun R, Yan J, Willis WD: Activation of protein kinase B/Akt in the
periphery contributes to pain behavior induced by capsaicin in rats.
Neurosci 2007, 144:286–294.
54. Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Amaya
F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Stean T,
Morisset V, Grose D, Gunthorpe MJ, Chessell IP, Tate S, Green PJ, Woolf CJ:
The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral
inflammatory pain hypersensitivity. J Neurosci 2006, 26:12852–12860.
55. Ho C, O’Leary ME: Single-cell analysis of sodium channel expression in
dorsal root ganglion neurons. Mol Cell Neurosci 2011, 46:159–166.
56. Maruyama H, Yamamoto M, Matsutomi T, Zheng T, Nakata Y, Wood JN,
Maruyama H, Yamamoto M, Matsutomi T, Zheng T, Nakata Y, Wood JN,
Ogata N: Electrophysiological characterization of the tetrodotoxin-
resistant Na+ channel, Na(v)1.9, in mouse dorsal root ganglion neurons.
Pflugers Arch 2004, 449:76–87.
57. Wang JG, Strong JA, Xie W, Yang RH, Coyle DE, Wick DM, Wang JG, Strong
JA, Xie W, Yang RH, Coyle DE, Wick DM, Dorsey ED, Zhang JM: The
chemokine CXCL1/growth related oncogene increases sodium currents
and neuronal excitability in small diameter sensory neurons. Mol Pain
2008, 4:38.
58. Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN, Waxman SG: A
novel persistent tetrodotoxin-resistant sodium current in SNS null and
wild-type small primary sensory neurons. J Neurosci 1999, 19:RC43.
59. Dib-Hajj SD, Tyrrell L, Cummins TR, Black JA, Wood PM, Waxman SG: Two
tetrodotoxin-resistant sodium channels in human dorsal root ganglion
neurons. FEBS Lett 1999, 462:117–120.
60. Milligan ED, Watkins LR: Pathological and protective roles of glia in
chronic pain. Nat Rev Neurosci 2009, 10:23–36.
61. Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Zhang N,
Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim
JJ: A proinflammatory chemokine, CCL3, sensitizes the heat- and
capsasin-gated ion channel TRPV1. Proc Natl Acad Sci U S A 2005,
102:4536–4541.
62. Hensellek S, Brell P, Schaible HG, Brauer R, von Banchet GS: The cytokine
TNFα increases the proportion of DRG neurones expressing the TRPV1
receptor via the TNFR1 receptor and ERK activation. Mol Cell Neurosci
2007, 36:381–391.
Kao et al. Journal of Neuroinflammation 2012, 9:189 Page 12 of 13
http://www.jneuroinflammation.com/content/9/1/189
63. Khan AA, Diogenes A, Jeske NA, Henry MA, Akopian A, Hargreaves KM:
Tumor necrosis factor alpha enhances the sensitivity of rat trigeminal
neurons to capsaicin. Neuroscience 2008, 155:503–509.
64. Cheng JK, Ji RR: Intracellular signaling in primary sensory neurons and
persistent pain. Neurochem Res 2008, 33:1970–1978.
65. Shi TJ, Huang P, Mulder J, Ceccatelli S, Hokfelt T: Expression of p-Akt in
sensory neurons and spinal cord after peripheral nerve injury.
Neurosignals 2009, 17:203–212.
66. Zhuang ZY, Xu H, Clapham DE, Ji RR: Phosphatidylinositol 3-kinase activates
ERK in primary sensory neurons and mediates inflammatory heat
hyperalgesia through TRPV1 sensitization. J Neurosci 2004, 24:8300–8309.
67. Puhl HL 3rd: Ikeda SRJ: Identification of the sensory neuron specific
regulatory region for the mouse gene encoding the voltage-gated
sodium channel NaV1.8. J Neurochem 2008, 106:1209–1224.
68. Chu C, Zavala K, Fahimi A, Lee J, Xue Q, Eilers H: Transcription factors Sp1
and Sp4 regulate TRPV1 gene expression in rat sensory neurons. Mol
Pain 2011, 7:44.
69. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D: Sp1 is involved in Akt-
mediated induction of VEGF expression through an HIF-1-independent
mechanism. Mol Biol Cell 2004, 15:4841–4853.
70. Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, Bae IH, Park MJ, Yoon
SH, Kang SW, Lee SS, Choi KM, Um HD: Bcl-w promotes gastric cancer cell
invasion by inducing matrix metalloproteinase-2 expression via
phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006, 66:4991–4995.
doi:10.1186/1742-2094-9-189
Cite this article as: Kao et al.: CC chemokine ligand 2 upregulates the
current density and expression of TRPV1 channels and Nav1.8 sodium
channels in dorsal root ganglion neurons. Journal of Neuroinflammation
2012 9:189.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kao et al. Journal of Neuroinflammation 2012, 9:189 Page 13 of 13
http://www.jneuroinflammation.com/content/9/1/189
